|
|
Profile
|
Delegates :
President & CEO, Ei Yamada |
|
Incorporated :
December 17 , 1999 |
Paid in Capital :
33359 Million yen |
Employees :
121 人 |
Address :
Saito Bio-Incubator 7-7-15, Saito-asagi, Ibaraki OSAKA
〒567-0085
|
TEL/FAX :
/ |
URL：
https://www.anges.co.jp/ |
Attachment :
|
Mission/Background :
AnGes , Inc. is a biopharmaceutical company with the mission of providing patients suffering from diseases for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on the development of gene-based medicines, a next-generation biopharmaceutical.
|
|
Technology & Business
|
AnGes , Inc. was founded in December 1999 based on an innovative discovery by researchers at Osaka University. AnGes has already undergone the first stage of research and development, and is now in the second stage of realizing clinical application. For our lead product, HGF Plasmid (gene therapy) for the treatment of Chronic arterial occlusive disease, the company got the conditional and time-limited approval in March 2019. And its practicalizing started in September 2019 in Japan. This is the world’s first commercialization using the Plasmid DNA method. Development of NF-κB decoy oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases including, low back pain, and DNA vaccines for high blood pressure is also under way. Furthermore, AnGes started co-development of the DNA vaccine with Osaka University from March 2020 for COVID-19.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
HGF Plasmid
|
Phase3
|
Target: Critical Limb Ischemia
|
Conditional approval in 2019. For Approval by 2024 PMS is on progress
|
COVID-19 DNA Vaccine
|
Phase2
|
Target: COVID-19
|
Conducting P3 in Japan
|
NF-kB Decoy Oligonucleotide
|
Phase1
|
Target: Chronic Discogenic Low Back Pain
|
Start P2 study in the US
|
COVID-19 Treatment
|
Phase1
|
Target: COVID-19
|
Conduct P2a study
|
Hypertension DNA Vaccine
|
Phase1
|
Target: Hypertension
|
Plan next clinical trial
|
|
Highlights
|
-HGF Plasmid for Critical Limb Ischemia: Conditional approval in 2019. PMS on going for approval by 2024
-COVID-19 Vaccine and Treatment: Clinical Trial on going
-NF-kB Decoy Oligonucleotide for Chronic Discogenic Low Back Pain: Clinical Trail on going
|
|
Alliance strategy
|
License-out: HGF Plasmid (excluding Critical Limb Ischemia in the US and Japan), NF-kB Decoy Oligonucleotide, and Hypertension DNA Vaccine
Inquiry form: https://www.anges.co.jp/contact/
|
|
|